IP Library Granted Patent US 7,115,727
Granted Patent B2
US 7,115,727 · App. 10/435,751 · Granted Oct 3, 2006

Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer

Assignee: Agensys, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,115,727
App. No.
10/435,751
Granted
Oct 3, 2006
Kind
B2
Abstract

A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.

Claims (3)

1. An isolated polynucleotide that encodes a protein comprising the amino acid sequence of SEQ ID NO:3, wherein the polynucleotide comprises nucleotides 272 to 3946 of SEQ ID NO:2.

2. The polynucleotide of claim 1 , wherein T can also be U.

3. The polynucleotide of claim 1 , further comprising a promoter sequence operably linked to nucleotides 272–3946 of SEQ ID NO:2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2004
From: FARIS, MARY; CHALLITA-EID, PIA M.; JAKOBOVITS, AYA; RAITANO, ARTHUR B.; GE, WANGMAO
To: AGENSYS, INC.
Reel/Frame 014537/0943 →
Continuity (3)
Provisional Application 6042329000 · Nov 1, 2002
Provisional Application 6040430600 · Aug 16, 2002
Related Publication 20040053348A1 · Mar 18, 2004